Novo Nordisk clinical trial pipeline

18 trials changed in the last 30 days: 0 stopped, 12 with notable changes, 6 with minor changes only.

1. Notable

   Adverse Event Data Collection From the EUHASS Registry on…Adverse Event Data Collection From the EUHASS Registry on Turoctocog Alfa Pegol

   Primary and study completion pushed from Feb 1, 2026 to Dec 1, 2026

   Novo Nordisk A/S·Not specified· NCT04682145· Registry history of NCT04682145 on ClinicalTrials.gov (opens the registry)

   Updated Oct 8, 2026

2. Notable

   Regulatory Post Marketing Surveillance (rPMS) Study of Rybelsus…Regulatory Post Marketing Surveillance (rPMS) Study of Rybelsus (Oral Semaglutide) to Evaluate Safety and Effectiveness · Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea

   Primary completion pushed from Oct 30, 2026 to Aug 30, 2027

   Also in this update: Study completion pushed from Oct 30, 2026 to Oct 31, 2027

   Novo Nordisk A/S·Not specified· NCT05714683· Registry history of NCT05714683 on ClinicalTrials.gov (opens the registry)

   Updated Sep 18, 2026

3. Notable

   CBH COPI · Cities for Better Health Childhood Obesity Prevention…CBH COPI · Cities for Better Health Childhood Obesity Prevention Initiative

   Primary and study completion pushed from Dec 31, 2027 to Dec 31, 2028

   Novo Nordisk A/S·Not applicable· NCT06855563· Registry history of NCT06855563 on ClinicalTrials.gov (opens the registry)

   Updated Sep 16, 2026

4. Notable

   Research Study to Look at Long-term Treatment With a Medicine…Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 · Heart Failure Due to Transthyretin Amyloidosis

   Primary endpoint(s) modified

   Also in this update: Trial sites expanded: 35 → 38 locations; Study completion pushed from Aug 15, 2028 to Feb 9, 2030; and 1 more change in the last 30 days

   Novo Nordisk A/S·Phase 2· NCT06260709· Registry history of NCT06260709 on ClinicalTrials.gov (opens the registry)

   Updated Sep 30, 2026

5. Notable

   SCALA-TK-CM · Real-World Cohort Study

   Primary endpoint(s) modified

   Also in this update: Trial status changed: Not Yet Recruiting → Active, Not Recruiting

   Novo Nordisk A/S·Not specified· NCT07781371· Registry history of NCT07781371 on ClinicalTrials.gov (opens the registry)

   Updated Sep 30, 2026

6. Notable

   Research Study on How · Type 2 Diabetes Tolerate Switching From…Research Study on How · Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema

   Recruitment opened

   Novo Nordisk A/S·Phase 3· NCT07817251· Registry history of NCT07817251 on ClinicalTrials.gov (opens the registry)

   Updated Sep 30, 2026

7. Notable

   AMAZE 9 · Zenagamtide Tablets Help · Excess Body Weight Lose…AMAZE 9 · Zenagamtide Tablets Help · Excess Body Weight Lose Weight

   Recruitment opened

   Also in this update: Trial sites expanded: 37 → 41 locations

   Novo Nordisk A/S·Phase 3· NCT07720271· Registry history of NCT07720271 on ClinicalTrials.gov (opens the registry)

   Updated Sep 28, 2026

8. Notable

   AMAZE 7 · Zenagamtide Helps · Excess Body Weight Lose Weight…AMAZE 7 · Zenagamtide Helps · Excess Body Weight Lose Weight Compared to Semaglutide

   Recruitment opened

   Novo Nordisk A/S·Phase 3· NCT07668414· Registry history of NCT07668414 on ClinicalTrials.gov (opens the registry)

   Updated Sep 28, 2026

9. Notable

   Patient Preferences · Haemophilia A With and Without Inhibitors: a…Patient Preferences · Haemophilia A With and Without Inhibitors: a Discrete Choice Experiment in Germany

   Enrolling by invitation only

   Also in this update: Primary and study completion pushed from Oct 26, 2026 to Dec 26, 2026

   Novo Nordisk A/S·Not specified· NCT07653139· Registry history of NCT07653139 on ClinicalTrials.gov (opens the registry)

   Updated Oct 6, 2026

10. Notable

    Research Study Looking at the Effect of Timing of Meal After…Research Study Looking at the Effect of Timing of Meal After Dosing and Water Volume at Dosing on How the Medicine Zenagamtide is Taken up by the Body · Overweight or Obesity

    Recruitment opened

    Novo Nordisk A/S·Phase 1· NCT07815067· Registry history of NCT07815067 on ClinicalTrials.gov (opens the registry)

    Updated Oct 2, 2026

11. Notable

    See How Safe a New Medicine (NNC0705-0002) is in Healthy People

    Recruitment opened

    Novo Nordisk A/S·Phase 1· NCT07797855· Registry history of NCT07797855 on ClinicalTrials.gov (opens the registry)

    Updated Sep 30, 2026

12. Notable

    ICOSWITCH REAL · Research Study to Examine Blood Sugar Control…ICOSWITCH REAL · Research Study to Examine Blood Sugar Control, Treatment Satisfaction and Adherence · Type 2 Diabetes After Switching From Daily Basal Insulin to Once-weekly Insulin Icodec

    Enrolling by invitation only

    Novo Nordisk A/S·Not specified· NCT07632404· Registry history of NCT07632404 on ClinicalTrials.gov (opens the registry)

    Updated Sep 18, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.